RMP UpdateRisk Management PlanRMP RevisionPharmacovigilance Risk MinimisationRMP Writing Support

RMP Update Case Study: Pharmacovigilance Risk Management Plan Support

See how PVCON helped a pharmaceutical company update its RMP after a new safety concern emerged, resolving regulatory comments and protecting submission timelines.

PVCON Team4 min read
Client
Pharmaceutical company
Focus
RMP update, safety assessment, pharmacovigilance plan and risk minimisation strategy
Duration
5 weeks
Pharmacovigilance RMP update process showing safety assessment and risk management revision

Results

to complete the updated RMP
5 weeksto complete the updated RMP
regulatory comments resolved
11regulatory comments resolved
review cycle to resolve them
1review cycle to resolve them
major restructuring requests
0major restructuring requests

Updating the RMP Before Time Ran Out

How PVCON helped a pharmaceutical company update its Risk Management Plan after a new safety concern emerged while maintaining regulatory submission timelines.

A New Safety Concern Changed the Risk Management Landscape

A pharmaceutical company preparing a regulatory submission identified new safety information that affected the assumptions within its existing Risk Management Plan (RMP).

The available safety information required reassessment of the product’s identified and potential risks, along with a review of whether existing pharmacovigilance activities and risk minimisation measures remained appropriate.

The challenge was timing.

The RMP update needed to be completed within a limited submission window while ensuring that the revised document accurately reflected the updated safety profile and regulatory expectations.

The company required specialised RMP writing support to reassess the risk-management strategy, update relevant sections and prepare a submission-ready document.

From safety signal to submission: an RMP update moving from safety concern identified through safety review, risk assessment, RMP update, aRMMs where applicable and regulatory submission to the submission deadline

Reassessing the RMP Around the Updated Safety Profile

PVCON reviewed the existing RMP structure and assessed how the new safety information affected the overall risk-management approach.

The engagement focused on evaluating the impact of the safety concern, updating relevant risk-management sections and ensuring alignment between safety information, pharmacovigilance activities and risk minimisation measures.

The support included:

  • Review of existing RMP sections
  • Assessment of new safety information
  • Update of safety concerns and risk characterisation
  • Revision of pharmacovigilance activities
  • Review of risk minimisation measures
  • Preparation of the revised RMP for submission

The updated approach ensured that the RMP reflected the current understanding of the product’s safety profile while maintaining consistency across related pharmacovigilance documentation.

What Needed to Be Updated

RMP AreaChallenge IdentifiedPVCON SupportOutcome
Safety ProfileNew safety information affected existing risk assessmentReassessed identified and potential risksUpdated safety considerations incorporated
Pharmacovigilance PlanExisting activities required reviewUpdated monitoring activities and commitmentsRevised PV strategy aligned with current risks
Risk MinimisationExisting measures required reassessmentReviewed and updated risk minimisation approachMeasures aligned with updated safety concerns
Regulatory CommentsMultiple points required resolution before submissionPrepared responses and revised documentation11 comments resolved in one review cycle
Submission TimelineLimited time available for completionManaged accelerated RMP update workflowRMP completed within 5 weeks

Detailed RMP update timeline from safety concern identified through safety review and risk assessment to an RMP update that incorporates new signals and the updated safety profile, additional risk minimisation measures if applicable, and regulatory submission ahead of the deadline

Delivering a Submission-Ready RMP Within a Critical Timeline

Through focused assessment and coordinated review, PVCON completed the updated RMP within 5 weeks.

The revised document addressed the emerging safety concern while maintaining alignment between risk characterisation, pharmacovigilance activities and risk minimisation measures.

During regulatory review, all 11 comments were resolved within one review cycle, with no major restructuring requested.

The outcome was not only a completed document.

The organisation had a more current and defensible risk-management strategy that reflected the updated safety profile and supported the next stage of regulatory engagement.

Keeping Risk Management Aligned Throughout the Product Lifecycle

An RMP is not a one-time submission document.

As new safety information emerges, organisations need to reassess whether existing risk characterisation, pharmacovigilance activities and risk minimisation measures remain appropriate.

A delayed or poorly structured update can create avoidable pressure during regulatory interactions.

For this pharmaceutical company, timely RMP revision helped maintain submission readiness while ensuring the risk-management approach remained aligned with current safety information.

PVCON supports organisations with RMP and REMS writing services, including risk assessment, risk minimisation strategy development and lifecycle updates.

Need support with an RMP update? Explore PVCON's pharmacovigilance medical writing support or contact PVCON to discuss your risk-management requirements.